Summary
This article presents the state of the art of immunoscintigraphy (IS) of ovarian cancer. We will review the monoclonal antibodies (MoAbs) used in clinical trials: (HMFG1/2, OC125, H317, H17E2, NDOG2 and 791T/36). We conclude that none of the afore mentioned MoAbs are clearly superior and that IS cannot yet replace laparotomy for the diagnosis of overian cancer but may have a role in the follow-up of ovarian cancer, in timing second-look surgery and assessing the response/TD treatment.
Similar content being viewed by others
References
Alvarez RD, To A, Boots LR, Shingleton HM, Hatch KD, Hubbard J, Soong SJ, Potter ME (1987) CA125 as serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 26:284–289
American Cancer Society (1981) Cancer facts and figures 1981. American Cancer Society, New York
Atack DB, Nisker JA, Allen HH, Tustanoff FR, Levin L (1986) CA125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 154:287–289
Baldwin RW, Byers VS (1986) Monoclonal antibodies in cancer treatment. Lancet I:603–605
Barzen G, Langer M, Becker R, Koppenhagen K, Felix R (1987) Radioimmunoscintigraphy (RIS) of ovarian cancer with iodine-131 labelled F(ab′)2 fragments of anti-CEA and OC125. Advances in the applications of monoclonal antibodies in clinical oncology, London, May 6–8
Bast RC, Freeny M, Lazarus H, Nadler LM, Colpin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Brukowitz R, Leuwitt T, Griffiths T, Parker R, Zunawsk VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887
Baum RP, Albrecht M, Thaler CJ, Happ J, Manegold K, Berthold F, Buhl R, Lorenz M, Hör G (1987) Immunoscintigraphy of ovarian cancer with monoclonal antibody OC125: first results. Nuklearmedizin 26:417
Chatal J, Fumoleau P, Saccavini J, Thedrez P, Gurtet, C, Bianco-Anco A, Chetanneau A, Pettier P, Kuemer M, Guillard Y (1987) Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med 28:1807–1819
Critchley M, Brownless S, Patten M, McLaughin PJ, Tromans PM, McDicken IW, Johnson PM (1986) Radionuclide imaging of epithelial ovarian tumours with I-123 labelled monoclonal antibody (H317) specific for placental-type alkaline phosphatase. Clin Radiol 37:107–112
Davies JO, Davies ER, Howe K, Jackson PC, Pitcher EM, Sadowski CS, Stivvat GM, Sunderland CA (1985) Radionuclide imaging of ovarian tumours with I-123 labelled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase. Br J Obstet Gynaecol 92:277–286
Doherty PW, Griffin T, Rusckowski M, Gionet M, Hunter R, Hnatowich DJ (1986) The potential utility of In-111 labeled OC125 antibody in patients with gynecological tumors. J Nucl Med [Suppl] 27:881
Einhorn N, Nilsson B, Sjovall K (1985) Factors influencing survival in carcinoma of the ovary. Cancer 55:2015–2019
Epenetos AA, Mather S, Granowska M, Nimmon CC, Hawkins LR, Britton KE, Shepherd JH, Taylor-Papadimitriou J, Durbin H, Malpas JS (1982) Targeting of iodine-123-labelled tumorassociated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. Lancet II:939–1005
Epenetos AA, Shepard JH, Britton KE, Hawkins LR, Nimmon CC, Taylor-Papadimitriou J, Durbin H, Malpas JS, Mather S, Granowska M, Duke D, Bodmer WF (1984) Radioimmunodiagnosis of ovarian cancer using I-123 labelled, tumour-associated monoclonal antibodies. Cancer Detect Prev 7:45–49
Epenetos AA, Shepard JH, Britton KE, Mather S, Taylor-Papadimitriou J, Granowska M, Durbin H, Nimmon CC, Hawkins LA, Malpas JS, Bodmer WF (1985a) I-123 radioiodinated antibody imaging of occult ovarian cancer. Cancer 55:984–987
Epenetos AA, Hooker G, Durbin H, Bodmer WF, Snook D, Regent R, Oliver R, Lavender JP (1985b) Indium labelled monoclonal antibody to placental alkaline phosphatase in the detection of testis, ovary, and cervix. Lancet II:350–353
Epentos AA, Carr D, Johnson PM, Bodmer WF, Lavender JP (1986a) Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase. Br J Radiol 59:117–125
Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986b) Limitations of radio-labeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183–3191
Epenetos AA, Lavender JP, Kenemans P, Poels L (1987a) Early results of the monoclonal OVTL3 in specific detection of ovarian cancer. J Clin Oncol 5:160
Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert H, McKenzie CG, Souther P, Rahemtulla A, Hooker G, Sivolapenko GB, Snook D, Courtney-Lock N, Dhokia B, Krausz T, Taylor-Papadimitriou J, Durbin H, Bodmer WF (1987b) Antibody-guided irradiation of ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890–1899
Fleuren GJ, Coercamp EG, Nap M, van de Broek LJCM, Warnaar SO (1987) Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas. Virchows Arch [A] 410:481–486
Gallup DG, Talledo OE, Dudzunski MR, Brown KW (1987) Another look at the second-assessment procedure for ovarian epithelial carcinoma. Am J Obstet 157:590–596
Granowska M, Britton KE, Shepard JH (1984a) The detection of ovarian cancer using I-123 monoclonal antibody. Radiobiol Radiother 25:153–160
Granowska M, Shepard J, Britton KE, Ward B, Mather S, Taylor-Papadimitriou J, Epenetos AA, Carroll MJ, Nimmon CC, Hawkins LA, Slevin M, Flatman W, Horne J, Burchell J, Durbin H, Bodmer W (1984b) Ovarian cancer: diagnosis using I-123 monoclonal antibody in comparison with surgical findings. Nucl Med Commun 5:485–499
Granowska M, Britton KE, Shepard JH, Nimmon CC, Mather S, Ward B, Osborne RJ, Slevin MJ (1986) A prospective study of I-123 labeled monoclonal antibody imaging in ovarian cancer. J Clin Oncol 4:730–736
Haisma HJ, Battaile AI, Knapp RC, Zurawski VR (1986) Immune complexes of OC125-CA125 following intravenous injection of the radiolabelled monoclonal antibody into ovarian cancer patients. Br J Cancer 54:533
Haisma HJ, Moseley KR, Battaile AI, Griffiths TC, Zurawski VR, Knapp RC (1988) Biodistribution pharmacokinetics and imaging of I-131 labelled OC125 in ovarian cancer. Int J Cancer [Suppl] 2:2
Herry JY, Kerbrat P, Bourget P, Toussaint C (1987) Immunoscintigraphy (IS) of ovarian carcinoma using the OC125 monoclonal antibody labelled with iodine-131. European Nuclear Medicine Congress, Budapest, August 24–28
Ho AG, Beller V, Speyer JL, Colomto N, Wernz J, Beckman EM (1987) A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J Clin Oncol 5:1316–1321
Hunter RE, Doherty P, Thomas WS, Griffin TW, Gionet N, Hnatowich DJ, Bianco JA, Dillon MB (1987) Use of Indium-111 labeled OC125 monoclonal antibody in the detection of ovarian cancer. Gynecol Oncol 27:325–337
Kenemans P, Verheijen RHM, Leloux AM, Poels LG (1985) Prospects and applications of monoclonal antibodies in gynecological oncology. Europ J Gynecol Reprod Biol 19:340–347
Niloff JM, Knapp RC, Lavin PT, Halkasian GB, Berck JS, Hortel R, Whitney S, Zurawski VR, Bast RC (1986) The CA125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155:56–60
O'Conell GJ, Eamonn R, Murphy KJ, Prefontaine M (1987) Predictive value of CA125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol 70:930–932
Pateisky N, Philipp K, Skodler WD, Czerwenka K, Hamilton G, Burchell J (1985) Radioimmunodetection in patients with suspected ovarian cancer. J Nucl Med 26:1369–1376
Poels LG, Peters D, Megen YV, Vooijs GP, Verheyen R, Willemen A, van Niekerk CC, Jap P, Mungyen G, Kenemans P (1986) Monoclonal antibody against human ovarian tumour associated antigen. JNCI 76:781–791
Rankin EM, McVie JG (1983) Radioimmunodetection of cancer: problems and potential. Br Med J 287:1402–1405
Shepherd JH, Epenetos AA, Britton KE, Ward BG, Granowska M, Bodmer WF (1983) Radioimmune diagnosis of ovarian carcinoma using tumor-associated monoclonal antibodies. Gynecol Oncol 53:134
Shepherd JH, Granowska M, Britton KE, Mather S, Epenetos AA, Ward BG, Slevin S (1987) Tumor-associated monoclonal assessment of ovarian cancer. Br J Obstet Gynaecol 94:160–167
Symonds EM, Perkins AC, Pimm MV, Baldwin RW, Hardy JG, Williams DA (1985) Clinical implications for immunoscintigraphy in patients with ovarian malignancy: a preliminary study using monoclonal antibody IT/36. Br J Obstet Gynaecol 92:270–276
Van Ginneken JKS, van der Vlist WP (1985) Kankersterfte in Nederland laatste 30 jaar meer dan verdubbeld. Kanker 9:4–9
Van Nagell JR, Donaldson ES, Hanson MB, Guy EC, Paulik EJ (1981) Biochemicals in plasma and tumors of patients with gynecologic malignancies. Cancer 48:495–501
Ward BG, Mather SJ, Hawkins LR, Crowther ME, Shepherd JH, Granowska M, Britton KE, Slevin M (1987) Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res 47:4719–4723
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Kranenburg, D.L., van Kroonenburgh, M.J.P.G., Trimbos, J.B. et al. Imaging of ovarian cancer with radiolabelled monoclonal antibodies. Arch Gynecol Obstet 247, 107–116 (1990). https://doi.org/10.1007/BF02390857
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02390857